Loading, Please Wait...

CST: 19/03/2019 11:07:49   

Dermavant Sciences to Present Data on Tapinarof for Psoriasis and Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting

26 Days ago

  • Dermavant plans to initiate Phase 3 clinical program evaluating tapinarof for the treatment of psoriasis in the first half of 2019

BASEL, Switzerland and PHOENIX, Feb. 21, 2019 (GLOBE NEWSWIRE) --  Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present data on tapinarof at the 2019 American Academy of Dermatology (AAD) Annual Meeting taking place March 1-5, 2019, in Washington, D.C.

Dermavant will present secondary efficacy outcomes from a Phase 2b study of tapinarof for the treatment of psoriasis and secondary outcomes from a Phase 2b study of tapinarof for the treatment of atopic dermatitis both in poster format and oral presentations.   

Dermavant is developing its lead product candidate, tapinarof, as a potentially first-in-class therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of psoriasis and atopic dermatitis, which affect approximately 7.5 million and 28 million people in the United States, respectively. Dermavant believes that tapinarof, if approved by the U.S. Food and Drug Administration, could provide an innovative topical treatment option for those inflammatory skin diseases. The company plans to initiate its Phase 3 clinical program evaluating tapinarof for the treatment of psoriasis in the first half of 2019.

Posters, along with dates, times, and locations of data sessions, are highlighted below:

Secondary efficacy outcomes from a phase 2b, randomized dose-finding study of tapinarof cream for the treatment of plaque psoriasis
Linda Stein Gold, M.D. (presenter), Henry Ford Health System

Dates/Times/Location:

  • ePoster Viewing: Friday, March 1, through Sunday, March 3, 9:00am-5:00pm ET
  • Presentation: Saturday, March 2, 5:05pm ET
  • Location: Walter E. Washington Convention Center; Hall D

Treatment of atopic dermatitis with tapinarof cream: Secondary outcomes from a phase 2b, randomized parallel-group study
Amy Paller, M.D. (presenter), Northwestern University Feinberg School of Medicine  

Dates/Times/Location:

  • ePoster Viewing: Friday, March 1, through Sunday, March 3, 9:00am-5:00pm ET
  • Presentation: Friday, March 1, 1:05pm ET
  • Location: Walter E. Washington Convention Center; Hall D

About Dermavant
Dermavant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. The company’s development pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing markets, psoriasis and atopic dermatitis, as well as other large markets, including acne, primary focal hyperhidrosis, and vitiligo. Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a potentially first-in-class therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of psoriasis and atopic dermatitis, which affect approximately 7.5 million and 28 million people in the United States, respectively. 

For more information about Dermavant, please visit www.dermavant.com.

CONTACT:
Kara Stancell
kara.stancell@dermavant.com  
520.858.0027

Is your business listed correctly on America’s largest city directory network of 1,000 portals?